<DOC>
	<DOC>NCT02617784</DOC>
	<brief_summary>This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD). Participants will receive 6.5 and 6 weeks of the marketed oral oseltamivir suspension dosed according to the HD or CAPD schedule, respectively.</brief_summary>
	<brief_title>A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Adults greater than or equal to (&gt;/=) 18 years of age ESRD defined as no residual renal function or a creatinine clearance (CrCl) less than (&lt;) 10 milliliters per minute (mL/min) Well established HD or CAPD therapy over a period of 3 months with stable CrCl &lt; 10 mL/min Body mass index (BMI) 18 to 34 kilograms per metersquared (kg/m^2) Use of contraception among women of childbearing potential Clinical significant comorbid disease or terminal illness Known human immunodeficiency virus (HIV) or hepatitis B or C History of drug or alcohol abuse within the prior year Donation or loss of &gt;/= 400 milliliters (mL) of blood in the 3 months prior to Screening Participation in a clinical study with an investigational drug in the 3 months prior to study drug Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>